A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients

The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.

开始日期2025-03-01

申办/合作机构

山东第一医科大学第一附属医院（山东省千佛山医院、山东省牙病防治指导中心）

NCT06578078

/ Recruiting临床3期IIT

A Randomized Clinical Trial to Define the Best Strategy for the Management of Heart Failure and Chronic Kidney Disease Among Elderly Patients With or at High Risk of hyperKalemia in Span by Optimizing the Use of RAASi With SZC

Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.

开始日期2024-10-03

申办/合作机构-

IRCT20130313012810N11

/ SuspendedN/AIIT

Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)

开始日期2024-08-31

申办/合作机构

Tabriz University of Medical Sciences

100 项与环硅酸锆钠相关的临床结果

登录后查看更多信息

100 项与环硅酸锆钠相关的转化医学

登录后查看更多信息

100 项与环硅酸锆钠相关的专利（医药）

登录后查看更多信息

286

项与环硅酸锆钠相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice

Article

作者: Merlo, Andrea ; Mongelli, Valentina ; Degli Esposti, Luca ; Maurizi, Anna Rita ; Leogrande, Melania ; Cosentino, Nicola ; Nugnes, Marta ; Gnesi, Marco ; Daniel, Francesca

AIMS:

Hyperkalemia (HK) is prevalent in patients with chronic kidney disease (CKD) and heart failure, particularly those on renin-angiotensin-aldosterone system inhibitors (RAASi). However, HK treatment often necessitates RAASi discontinuation. Sodium zirconium cyclosilicate (SZC), reimbursed in Italy since 2021, offers a new treatment option for HK. This study aimed to assess real-world SZC use and resulting economic rebounds in Italy.

METHODS:

Using administrative databases of healthcare entities covering about 6 million residents, patients with at least one prescription of SZC from Jan-2022 to Jun-2023 were identified. Patients receiving other potassium binders after SZC initiation were excluded. A logistic regression model estimated odds ratios (OR) with 95% confidence interval (95%CI) for predictors of long-term SZC use (>90 days), including age, sex, CKD status, and comorbidities. Univariate regression identified the potential association between each individual predictor and the likelihood of long-term treatment, followed by multivariate analysis adjusted for confounders. A backward stepwise logistic regression method retained only significant predictors, enhancing model accuracy.

RESULTS:

The study identified 355 SZC-treated patients (mean age 70.4 years, 64.2% male). CKD was found in 69.3% (47.6% on dialysis), with common comorbidities including hypertension (57.5%), diabetes (43.4%), and heart failure (23.4%). RAASi use was observed in 68.7% before SZC initiation, and RAASi discontinuation was lower in long-term SZC users compared to short-term SZC users (41.2 vs. 56.6%, p = 0.048). Short-term SZC treatment (≤90 days) was more frequent (83.1%) and predicted by dialysis (OR = 0.22). Healthcare costs over 6 months averaged €7,943 for short-term users (dialysis: €3,452) and €6,647 for long-term users (dialysis: €1,130).

CONCLUSIONS:

This real-world study showed that nearly 17% of patients continued SZC therapy for ≥90 days. Long-term therapy was associated with lower RAASi discontinuation and reduced healthcare costs due to hospitalizations and outpatient specialist services, suggesting that SZC can potentially provide clinical and economic benefits for HK management.

2025-12-01·Stress biology

Genetic characterization of the AHAS mutant line K4 with resistance to AHAS-inhibitor herbicides in rapeseed (Brassica napus L.)

Article

作者: Hu, Zhaoxin ; Huang, Qianxin ; Guo, Yuan ; Hu, Shengwu ; Qu, Gaoping ; Gao, Lianliang ; Wang, Shengnan ; Zhang, Yani

Abstract:

It remains a great challenge to control weeds in rapeseed fields in China. Breeding herbicide-resistant rapeseed varieties and using corresponding herbicide formulations has become the most economical and effective way to control weeds in rapeseed field. Characterization of more herbicide-resistant genetic resources will provide opportunities for breeders to develop rapeseed herbicide-resistant varieties with good agronomic performance. Previously, we obtained the tribenuron methyl (TBM)-resistant mutant K4 from ZS9 (Brassica napus L.) through ethyl methyl sulfonate mutagenesis and TBM foliar-spray screening. In this study, the inheritance and molecular characterization of the mutant K4 are carried out. Genetic investigation indicated that the herbicide-resistance of the K4 was controlled by one dominant allele at a single nuclear gene locus. Molecular characterization showed that a single point substitution at position 535 from C to T in BnAHAS3 (BnAHAS3535T), which resulted in a mutation at point 179 in BnAHAS3. The K4 showed a certain degree of resistance to TBM, bensulfuron methyl, and monosulfon sodium, which were 50, 30, and 5 times that of ZS9, respectively. AHAS enzyme assay, structural analysis of AHAS proteins, affinity detection between TBM and BnAHAS3 by surface plasmon resonance analysis, and the transgenic experiment in Arabidopsis using BnAHAS3535T confirmed that BnAHAS3535T endow the K4 with herbicides resistance. In addition, an allele-specific marker was developed to quickly distinguish the heterozygous and homozygous mutated alleles BnAHAS3535T. In conclusion, our research identified and characterized one novel mutative AHAS allele in B. napus and enriched genetic resource for developing herbicide-resistant rapeseed cultivars.

2025-09-01·European Journal of Hospital Pharmacy

Comparison of sodium zirconium cyclosilicate and sodium polystyrene sulfonate in the treatment of acute hyperkalaemia

Article

作者: Iso, Tomona ; Thai, Tommy ; Hong, Lisa ; Hauschild, Christopher

OBJECTIVE:

Sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC) have been used for treating acute hyperkalaemia. The pharmacodynamic properties of SZC suggest greater theoretical utility in the acute setting than SPS, but there is no clear guidance on an optimal potassium binder. This study evaluated the efficacy of SZC and SPS in the treatment of acute hyperkalaemia.

METHODS:

This retrospective cohort study included adult hospitalised patients who had acute hyperkalaemia (serum potassium level ≥5.5 mmol/L) and were treated with either SZC or SPS from April 2021 to August 2023. The primary outcome was time to first occurrence of potassium normalisation which was evaluated using Cox regression analysis. Secondary outcomes included potassium normalisation, serum potassium level trends, newly initiated dialysis following acute hyperkalaemia, in-hospital death and adverse events.

RESULTS:

The study included 46 patients with 17 in the SZC group and 29 in the SPS group. Potassium normalisation was attained in 16 (94%) in the SZC group and 27 (93%) in the SPS group and, of those, five (29%) in the SZC group and five (17%) in the SPS group attained normal potassium levels within 8 hours (HR 1.91, 95% CI 0.55 to 6.56).

CONCLUSION:

Statistically, neither SZC nor SPS was more efficacious; however, the quicker onset of SZC could provide a clinically meaningful difference in the treatment of acute hyperkalaemia.

项与环硅酸锆钠相关的新闻（医药）

2025-09-05

·国际糖尿病idiabetes

非奈利酮治疗慢性肾脏病：从机制到临床实践的革新突破

点击“蓝字”关注我们编者按：慢性肾脏病（CKD）作为全球重大公共卫生挑战，亟待新的有效治疗策略。盐皮质激素受体（MR）过度激活是推动CKD炎症、纤维化及肾功能恶化的核心机制与关键靶点；而新型高选择性非甾体类MR拮抗剂（MRA）非奈利酮，凭借其独特优势，为CKD管理带来了新希望。近期青岛大学附属医院内分泌代谢科王颜刚教授团队、董冰子等完成的综述《非奈利酮治疗慢性肾脏病：机制、疗效与安全性》发表于知名期刊Diabetes/Metabolism Research and Reviews(IF=6.0)[1]。董教授强调该综述源于紧迫的临床需求及非奈利酮关键III期试验证实的显著心肾保护作用；非甾体MRA可以强效拮抗MR的过度激活，同时显著降低传统MRA相关的高钾血症及性激素紊乱的风险；其临床价值高度契合治疗策略革新与心血管-肾脏-代谢综合征（CKM）理念。本综述系统地梳理了非奈利酮"机制-疗效-实践"全景图，为优化CKD治疗路径提供了重要参考。一、精准干预：MR过度激活与非奈利酮的作用机制 MR在肾脏、心脏和血管中广泛表达，其过度激活可导致钠水潴留、炎症和纤维化，进而引起肾小球硬化、足细胞损伤及肾小管间质纤维化[2]。在与肾素-血管紧张素系统（RAS）协同作用下，血管紧张素II（Ang II）促进醛固酮分泌，进一步激活MR，形成恶性循环并加剧心肾损伤[3]。非奈利酮作为第三代非甾体类MRA，通过高选择性拮抗MR，阻断IL-6、TNF-α、NLRP3等促炎信号和TGF-β等促纤维化通路[4]。其独特分子结构可诱导MR构象改变，抑制辅激活因子募集，即便无醛固酮存在仍可发挥拮抗作用[5]。药理学上，非奈利酮具有在心肾组织分布均衡（心肾比1:1）、半衰期短（2–3小时）、几乎无性激素受体亲和力等优势，从而降低了相关不良事件的风险[6]。临床前研究表明，该药能显著降低糖尿病大鼠肾损伤标志物（Kim-1、Ngal），抑制炎症与氧化应激，延缓纤维化进展[7]。二、临床研究进展：突破CKD治疗困境非奈利酮的临床价值在多项大规模随机对照研究中得到验证。FIDELIO-DKD和FIGARO-DKD两项III期研究共纳入超过1.3万名T2DM合并CKD患者，结果显示非奈利酮显著降低肾脏复合终点风险达18%~23%，心血管事件风险降低14%[8,9]。 FIDELITY荟萃分析（n=13 026）也进一步证实，非奈利酮可将终末期肾病（ESKD）进展风险降低20%[10]。值得关注的是，亚洲人群似乎从非奈利酮治疗中获益更显著。FIDELITY亚组分析显示，亚洲患者（n=2858）eGFR年下降速率较安慰剂延缓达1.08 ml/min/1.73m2。在UACR30 ~300mg/g患者中，39.5%的患者实现了微量白蛋白尿“转阴”[11]。除CKD人群外，非奈利酮的应用范围正逐步向心衰领域扩展。FINEARTS-HF研究显示，在左心室射血分数≥40%的心衰患者中，非奈利酮可降低心血管死亡及心衰事件风险16%，为合并CKD的心衰患者提供了新的治疗选择[12]。三、联合治疗：优化心肾保护的“黄金组合” 目前，在CKD的管理中，多靶点联合治疗成为重要策略。研究发现，非奈利酮与RAS抑制剂（ACEI/ARB）联用可进一步降低蛋白尿，但需注意高钾血症风险——尽管其发生率仍显著低于传统MRA[13]。值得注意的是，FIDELIO-DKD研究显示，基线使用RASi不会额外增加高钾血症风险[14]。更令人鼓舞的是，非奈利酮与钠-葡萄糖协同转运蛋自2抑制剂(SGLT2i)机制互补，两者具有协同效应。并且SGLT2i通过利钠作用间接促进了尿钾排泄，可能部分抵消了非奈利酮的高钾风险[15]。临床前研究显示，非奈利酮与SGLT2i联用在大鼠模型中显著降低高血压相关死亡率及肾损伤[16]；而FIDELITY亚组分析发现，基线使用SGLT2i的患者高钾血症发生率更低[17]；最近发表的CONFIDENCE研究显示，非奈利酮与SGLT2i早期联合治疗可显著降低UACR，2周降幅可达30%，并在180天降幅达到52%，较非奈利酮或SGLT2i单药治疗额外降低UACR约30%（P<0.001），显示出显著的协同效应[18]。此外，一项发表于Circulation的荟萃分析指出，在射血分数轻度降低或保留的心衰（HFmrEF/HFpEF）患者中，联合使用非奈利酮与SGLT2i与可进一步降低心血管事件风险，绝对风险降幅近乎翻倍（每100患者-年发生4.7次事件 vs. 2.5次事件），预示着“心肾代谢一体化管理”时代的到来[19]。四、安全性：突破传统MRA局限非奈利酮在安全性方面的表现，是其能否长期应用的关键。研究显示，与传统甾体类MRA相比，其高钾血症风险显著降低。在FIDELIO-DKD研究中，重度高钾血症（需住院或停药）发生率≤1.8%，远低于历史报告中螺内酯的数据[20]，REALIZE-K试验也证实了钾结合剂环硅酸锆钠在高风险患者中与MRA联用的安全性，为高钾血症管理提供了新策略[21]。在性激素相关副作用方面，非奈利酮几乎不拮抗雄激素受体，男性乳房发育、性功能障碍等风险极低，显著提高了患者依从性和生活质量[22]。对于长期治疗的CKD患者，是一个重要的临床优势。五、前景：从肾脏到心肾代谢一体化管理随着心血管-肾脏-代谢综合征（CKM）概念的提出（AHA 2023），CKD管理已不再局限于单一器官，而是强调多系统协同干预[23]。近年来，非奈利酮凭借其抗炎、抗纤维化和代谢调节的多重效应，目前已被2023 ESC指南列为Ⅰ类推荐，成为CKM综合征管理的核心药物之一。目前多项临床试验正在拓展其应用范围，包括原发性醛固酮增多症（NCT05924620）、膜性肾病（NCT06573411）等[24]，旨在进一步丰富非奈利酮的临床证据体系。结论非奈利酮作为第三代高选择性非甾体类MRA，通过抑制氧化应激、阻断炎症和纤维化，有效对抗MR过度激活，为T2DM合并CVD及CKD患者提供心血管和肾脏双重保护；同时减少高钾血症和不良激素效应等副作用，提高患者安全性。王颜刚教授点评王颜刚教授在临床中，T2DM合并CKD患者日益增多，二者相互加剧，形成恶性循环，内分泌科医生已成为CKD管理的第一道防线。非奈利酮凭借直接抗炎和抗纤维化机制，弥补了现有RASi和SGLT2i治疗的靶点不足，具有重要心肾保护临床价值。从亚洲人群数据来看，其在延缓eGFR下降、改善蛋白尿分期方面具有明确优势；FINEARTS-HF研究也为其在射血分数保留的心力衰竭（HFpEF）合并CKD患者中的应用提供了新依据。同时，CONFIDENCE研究证实了非奈利酮与SGLT2i联合使用的耐受性与协同增效作用。因此，对与T2DM合并CKD患者，建议实施早期干预——若UACR≥30 mg/g立即启动治疗评估，充分发挥“RASi+非奈利酮+SGLT2i”多重机制联合治疗的三重保护优势，从而最大程度地改善患者长期心肾结局。专家简介王颜刚青岛大学附属医院内分泌代谢科主任，主任医师，博士研究生导师。 2007年获华中科技大学同济医院中西医结合博士学位曾在美国Johns Hopkins University School of Medicine留学一年曾在英国Sheffield Teaching Hospital学习神经病变山东省齐鲁卫生与健康领军人才，青岛市拔尖人才。曾担任中华医学会糖尿病分会第七、八届委员中华医学会内分泌分会委员中国医师协会内分泌专业委员会常委中国中西医结合学会内分泌专业委员会副主任委员山东省医学会内分泌分会主任委员山东中西医结合学会内分泌专业委员会主任委员山东省老年学会会长荣获国家发明专利9项，承担科技部重点专项、国家自然基金、山东省重大基金、自然基金项目、青岛市重大项目等。担任中华内分泌代谢杂志编委，中华糖尿病杂志编委。董冰子青岛大学附属医院内分泌科，副主任医师，青岛大学特聘教授泰山学者青年专家，博士研究生导师，博士后合作导师留日医学博士（日本政府文部省奖学金留学生）哈佛医学院/麻省总医院MGH博士后Research Fellow，访问学者第一/通讯作者发表20余篇SCI论文，包括Nature Communications, J Bone Miner Res, Aging Dis等TOP期刊，主持国家自然科学基金2项，省部级课题3项山东省医学会骨质疏松和骨矿盐疾病专科分会委员，山东省医师协会骨质疏松及骨矿盐疾病分会委员，青岛医学会骨质疏松及骨矿盐疾病专科分会副主任委员 Journal of Diabetes, Burns & Trauma, Frontiers in Endocrinology，BTM等杂志编委、专刊客座编辑参考文献（上下滑动可查看） 1.Hu Y, Li C, Li S, Xu L, Wang Y, Dong B. Finerenone in Chronic Kidney Disease: A Comprehensive Review of Mechanisms, Efficacy and Safety. Diabetes Metab Res Rev. 2025 Sep;41(6):e70075. 2.E.Cantero‐Navarro, B. Fernández‐Fernández, A. M. Ramos, et al.,“Renin‐Angiotensin System and Inflammation Update,” Molecular and Cellular Endocrinology 529 (2021): 111254. 3.E.S. Kulthinee, A. Tasanarong, M. Franco, and L. G. Navar, “Interaction of Angiotensin II AT1 Receptors With Purinergic P2X Receptors in Regulating Renal Afferent Arterioles in Angiotensin II‐Dependent Hypertension,” International Journal of Molecular Sciences 24, no. 14(2023): 11413. 4.R. Lv, L. Xu, L. Che, S. Liu, Y. Wang, and B. Dong, “Cardiovascular‐Renal Protective Effect and Molecular Mechanism of Finerenone in Type 2 Diabetic Mellitus,” Frontiers in Endocrinology 14 (2023): 1125693. 5.L. Amazit, F. Le Billan, P. Kolkhof, et al., “Finerenone Impedes Aldosterone‐Dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator‐1,” Journal of Biological Chemistry 290, no. 36 (2015):21876–21889. 6.F. Gtzinger, M. Kunz, L. Lauder, M. B?hm, and F. Mahfoud, “New Ways of Mitigating Aldosterone in Cardiorenal Disease,”European Heart Journal Cardiovascular Pharmacotherapy 10, no. 6 (2024): 557–56. 7.M. Sanz‐Gómez, F. J. Manzano‐Lista, E. Vega‐Martín, et al.,“Finerenone Protects Against Progression of Kidney and Cardiovascular Damage in a Model of Type 1 Diabetes Through Modulation of Proinflammatory and Osteogenic Factors,”Biomedicine & Pharmacotherapy 168 (2023): 115661. 8.G. L. Bakris, R. Agarwal, S. D. Anker, et al., “Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes,” New England Journal of Medicine 383, no. 23 (2020): 2219–2229. 9.B. Pitt, G. Filippatos, R. Agarwal, et al., “Cardiovascular Events With Finerenone in Kidney Disease and Type 2 Diabetes,” New England Journal of Medicine 385, no. 24 (2021): 2252–2263. 10.G. L. Bakris, L. M. Ruilope, S. D. Anker, et al., “A Prespecified Exploratory Analysis From FIDELITY Examined Finerenone Use and Kidney Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes,” Kidney International 103, no. 1 (2023): 196–206. 11.D. Koya, S. D. Anker, L. M. Ruilope, et al., “Cardiorenal Outcomes With Finerenone in Asian Patients With Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO‐DKD Post Hoc Analysis,” American Journal of Nephrology 54, no. 9–10 (2023): 370–378F. 12.R. Mc Causland, M. Vaduganathan, B. L. Claggett, et al., “Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS‐HF Trial,” Journal of the American College of Cardiology 85, no. 2 (2025): 159–168. 13.C. Zuo and G. Xu, “Efficacy and Safety of Mineralocorticoid Receptor Antagonists With ACEI/ARB Treatment for Diabetic Nephropathy: A Meta‐Analysis,” International Journal of Clinical Practice 73, no.12 (2019): e13413. 14.R. Agarwal, A. Joseph, S. D. Anker, et al., “Hyperkalemia Risk With Finerenone: Results From the FIDELIO‐DKD Trial,” Journal of the American Society of Nephrology 33, no. 1 (2022): 225–237. 15.S. L. Kristensen, K. F. Docherty, P. S. Jhund, et al., “Dapagliflozin Reduces the Risk of Hyperkalaemia in Patients With Heart Failure and Reduced Ejection Fraction: A Secondary Analysis DAPA‐HF,” supplement, European Heart Journal 41, no. S2 (2020): ehaa946.0939. 16.P. Kolkhof, E. Hartmann, A. Freyberger, et al., “Effects of Finerenone Combined With Empagliflozin in a Model of Hypertension‐Induced End‐Organ Damage,” American Journal of Nephrology 52, no.8 (2021): 642–652. 17.P. Rossing, S. D. Anker, G. Filippatos, et al., “Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium‐Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis,” Diabetes Care 45, no. 12 (2022): 2991–2998. 18.Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025 Aug 7;393(6):533-543. 19.M. Vaduganathan, B. L. Claggett, I. J. Kulac, et al., “Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure,” Circulation 151, no. 2 (2025): 149–158. 20.F. D. R. Hobbs, R. J. McManus, C. J. Taylor, et al., “Low‐Dose Spironolactone and Cardiovascular Outcomes in Moderate Stage Chronic Kidney Disease: A Randomized Controlled Trial,” Nature Medicine 30, no. 12 (2024): 3634–3645. 21.M. N. Kosiborod, D. Cherney, K. Connelly, et al., “Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE‐K Design and Baseline Characteristics,” JACC Heart Failure 12, no. 10 (2024):1707–1716. 22.F. G?tzinger, M. Kunz, L. Lauder, M. B?hm, and F. Mahfoud, “New Ways of Mitigating Aldosterone in Cardiorenal Disease,” European Heart Journal Cardiovascular Pharmacotherapy 10, no. 6 (2024): 557–565. 23.C. E. Ndumele, I. J. Neeland, K. R. Tuttle, et al., “A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular‐Kidney‐Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association,” Circulation 148, no. 20 (2023): 1636–1664. 24.M. Epstein, “Considerations for the Future: Current and Future Treatment Paradigms With Mineralocorticoid Receptor Antagonists‐Unmet Needs and Underserved Patient Cohorts,” Kidney International Supplements 12, no. 1 (2022): 69–75. 声明：本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。最新《国际糖尿病》读者专属微信交流群建好了，快快加入吧！扫描左边《国际糖尿病》小助手二维码（微信号：guojitnb），回复“国际糖尿病读者”，ta会尽快拉您入群滴！（来源：《国际糖尿病》编辑部）版权声明版权属《国际糖尿病》所有。欢迎个人转发分享。其他任何媒体、网站未经授权，禁止转载。

临床3期临床终止临床结果临床2期

2025-09-04

·摩熵医药

49款新药IND获批！85个品种过评，成都倍特药业领跑

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 PART 01 周报概述随着全球医药行业的快速发展，新药研发与创新已成为推动行业进步的重要动力。近期，根据摩熵医药数据统计，新药申请与审批获批频繁，显示出医药创新领域的活跃态势。本文将深入分析2025年8月25日至2025年8月31日期间，国内外新药申请、临床试验批准、仿制药一致性评价等多个方面的最新进展，为用户提供全面的行业资讯。 PART 02 国内49款新药IND获批根据摩熵医药数据库统计，2025年8月25日至8月31日期间共有104个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号68个，进口药品受理号36个。本周共计49款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药23款，生物药25款，中药1款。本周获批临床创新药/改良型新药部分信息速览（不含补充申请）注：完整数据可识别“文末”二维码下载查看 PART 03 本周全球TOP10创新药研发进展在全球创新药研发领域，8月27日，百济神州宣布欧盟委员会（EC）已批准百泽安（抗PD-1单抗替雷利珠单抗）联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌（NSCLC）成人患者的新辅助治疗，并在手术后继续使用替雷利珠单抗单药进行辅助治疗。EC的此项批准是基于3期RATIONALE-315研究结果。该研究预先计划的最终分析表明，与化疗联合安慰剂相比，替雷利珠单抗在手术前联合含铂化疗进行新辅助治疗，并在手术后继续作为单药辅助治疗，取得了具有统计学显著性及临床意义的总生存期（OS）获益。具体数据将于2025年9月6日至9日在西班牙巴塞罗那举行的国际肺癌研究协会（IASLC）2025年世界肺癌大会（WCLC）上作为最新突破摘要公布。截图来源：摩熵医药全球药物研发数据库 8月29日，中国国家药监局宣布通过优先审评审批程序附条件批准恒瑞医药申报的1类创新药泽美妥司他片上市，该药品适用于既往接受过至少1线系统性治疗的复发或难治外周T细胞淋巴瘤成人患者。公开资料显示，这是恒瑞医药研发的新型、选择性口服EZH2抑制剂SHR2554，对野生型和突变型EZH2均表现出强抑制性。2024年6月，SHR2554治疗复发或难治外周T细胞淋巴瘤（PTCL）患者的II期临床试验（SHR2554-I-101）主要研究终点结果达到方案预设的优效标准。该研究II期阶段旨在评估SHR2554单药治疗复发或难治PTCL受试者的抗肿瘤疗效和安全性。主要研究终点为由独立影像评审委员会（IRC）基于Lugano 2014评估的客观缓解率（ORR）。截至2024年6月，共计67例患者接受SHR2554单药治疗，研究结果表明，与预设的历史数据相比，SHR2554单药在复发或难治PTCL患者中取得了显著的且有临床意义的改善。（相关详情请点击：又一个国产首款！恒瑞医药放“大招”）本周全球TOP10创新药研发进展截图来源：摩熵咨询周报 PART 04 本周全球TOP10临床试验结果本周全球多项临床试验结果亮点纷呈。8月25日，先声药业宣布，新型双食欲素受体拮抗剂（DORA）类抗失眠药达利雷生中国3期临床试验数据在世界睡眠研究协会官方出版物《睡眠》杂志（SLEEP）正式发表。结果显示：针对中国失眠人群，达利雷生在睡眠维持、加快入睡和延长睡眠时间等指标上均取得阳性结果，且清晨嗜睡发生率低。该随机、双盲、安慰剂对照、多中心研究由首都医科大学宣武医院王玉平教授担任牵头主要研究者，共纳入206例中国失眠患者，评估50mg达利雷生口服每晚一片对比安慰剂的疗效与安全性（治疗期1个月），关键结果如下：入睡后觉醒时间（WASO）：达利雷生组较基线的改善程度显著优于安慰剂组（-35.0min vs. -19.5 min, p=.0009）。与安慰剂相比，后半夜觉醒时间的改善幅度尤为突出（P<0.05）。睡眠潜伏期（LPS）：达利雷生组入睡时间与基线相比的缩短程度，显著优于安慰剂组（-35.7 vs. -22.2min，p=0.0031）。主观总睡眠时间（sTST）：达利雷生组主观睡眠总时间显著长于安慰剂组（50.3min vs. 33.5min, p=0.021），患者主观失眠感受减轻。双盲治疗期间达利雷生与安慰剂组的不良事件发生率相当（21.6% vs.18.4%）。停药后未观察到戒断症状、反跳性失眠，无次日残留效应。截图来源：摩熵医药全球药物研发数据库本周内，礼来（Eli Lilly and Company）取得了多项临床试验积极结果。8月26日，公布了其在研GLP-1受体激动剂orforglipron的3期临床试验ATTAIN-2的积极顶线结果。该研究针对合并2型糖尿病的肥胖或超重成人患者。在ATTAIN-2研究中，orforglipron的3个剂量组均达到了主要终点和所有关键次要终点，在72周时实现了显著的体重下降、具有临床意义的糖化血红蛋白（A1C）降低，及心血管风险因素的改善。在主要终点方面，每日一次且在不受食物或饮水限制的前提下，orforglipron 36mg组平均体重下降达10.5%（10.4kg），而安慰剂组为2.2%（2.3 kg）（使用有效性估计目标）。新闻稿表示，随着ATTAIN-2研究的完成，礼来已具备向全球监管机构递交orforglipron上市申请所需的全部临床数据。截图来源：摩熵医药全球药物研发数据库紧接着在8月27日，礼来又宣布其创新药物Verzenio（abemaciclib）显著提高了高危乳腺癌患者的总体生存期。截图来源：摩熵医药全球药物研发数据库这一里程碑式的成果来源于对III期monarchE试验的最新分析，进一步巩固了Verzenio在早期乳腺癌治疗中的关键地位。这项试验数据显示，对于激素受体阳性（HR+）、HER2阴性（HER2-）、淋巴结阳性、高危早期乳腺癌患者，接受两年Verzenio联合内分泌治疗，与单纯接受内分泌治疗相比，总生存期实现了统计学意义上的显著改善和临床意义上的有益提升。在monarchE试验的七年里程碑分析中，Verzenio治疗还持续显示出在浸润性无病生存期和远处复发无病生存期方面的益处。本周全球TOP10积极/失败临床结果截图来源：摩熵咨询周报 PART 05 85款品种过评！成都倍特药业领跑根据摩熵医药数据库统计，2025年8月25日至8月31日期间共有116项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号96项（包括化药3类，4类，5.2类），新注册分类临床申请受理号10项（包括化药3类，4类），一致性评价申请10项。本周13个品种通过一致性评价（按受理号计24项），本周72个品种视同通过一致性评价（按受理号计101项）。本周无生物类似物注册申报动态。本周过评/视同过评品种主要为系统用抗感染药物；过评/视同过评产品剂型主要为注射剂。截图来源：摩熵咨询周报本周注射用头孢哌酮钠舒巴坦钠过评/视同过评受理号数量最多达8个，本周二羟丙茶碱注射液、硫酸镁钠钾口服用浓溶液、枸橼酸西地那非片品种过评/视同过评企业最多达3家；本周成都倍特药业股份有限公司过评/视同过评品种数最多达3种，本周过评/视同过评企业共包括成都倍特药业股份有限公司、广州白云山天心制药股份有限公司、南京正科医药股份有限公司等84家企业。截图来源：摩熵咨询周报本周有二氟泼尼酯滴眼液、环硅酸锆钠散、克拉霉素干混悬剂、复方氨基酸注射液(18AA-Ⅶ-SF)、复方氨基酸注射液(18AA-Ⅸ-SF)、草酸艾司西酞普兰口服滴剂、甲巯咪唑片、注射用亚锡喷替酸8个品种为首次过评/视同过评。截图来源：摩熵咨询周报本周有氯化钾缓释片、复方甘草酸苷片、盐酸屈他维林注射液3个品种的过评/视同过评企业达到了7家。截图来源：摩熵咨询周报摩熵咨询本期完整周报识别二维码领取下载 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-202503 2024年中国1类新药靶点白皮书-202503 中国AI医疗健康企业创新发展百强榜单-202502 解码护肤抗衰：消费偏好洞察与市场格局分析-202502 2024年FDA批准上市的新药分析报告-202501 小分子化药白皮书（上）-202501 2024年中国医疗健康投融资全景洞察报告-202501 2024年医保谈判及市场分析报告-202501 近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

临床申请优先审批申请上市

2025-08-29

·EINPresswire

April - June 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Adcetris (brentuximab vedotin) Guillain-Barre syndrome FDA determined that no action is necessary at the time based on available information. Arzerra (ofatumumab) Gazyva (obinutuzumab) Riabni (rituximab-arrx) Rituxan (rituximab) Rituxan Hycela (rituximab and hyaluronidase human) Ruxience (rituximab-pvvr) Truxima (rituximab-abbs) Colitis FDA determined that no action is necessary at the time based on available information. Balversa (erdafitinib) Calciphylaxis The "Warnings and Precautions", "Patient Counseling Information", and the "Patient Information" sections of the labeling were updated in April 2022 to include information about soft tissue mineralization, including calciphylaxis. Balversa labeling Bavencio (avelumab) Keytruda (pembrolizumab) Opdivo (nivolumab) Yervoy (ipilimumab) Imfinzi (durvalumab) * Necrotizing fasciitis FDA determined that no action is necessary at this time based on available information. *An administrative error resulted in the omission of Imfinzi (durvalumab) from the list of product names. Imfinzi was added after the initial quarterly report was posted. Beta-blockers Betapace (sotalol hydrochloride) Brevibloc (esmolol hydrochloride) Bystolic (nebivolol) Byvalson (nebivolol and valsartan) Coreg (carvedilol) Coreg CR (carvedilol) Corgard (nadolol) Corzide (nadolol and bendroflumethiazide) Dutoprol (metoprolol succinate and hydrochlorothiazide) Kapspargo Sprinkle (metoprolol succinate) Lopressor HCT (metoprolol tartrate and hydrochlorothiazide) Sectral (acebutolol hydrochloride) Sotylize (sotalol hydrochloride) Tenoretic (atenolol and chlorthalidone) Toprol XL (metoprolol succinate) Trandate (labetalol hydrochloride) Ziac (bisoprolol fumarate and hydrochlorothiazide) Generic products containing beta-blockers Hemangeol (Propranolol Hydrochloride)* Inderal LA (Propranolol Hydrochloride)* Innopran XL (Propranolol hydrochloride)* Lopressor (metoprolol tartrate)* Tenormin (Atenolol)* Hypoglycemia in pediatric patients The "Warnings and Precautions" and "Patient Counseling Information" sections of the labeling were updated between March 2023 and June 2024 to add additional information regarding hypoglycemia. Example: Coreg labeling An administrative error resulted in the inclusion of Betapace AF, Levatol, and Zebeta in the list of product names at the time of the initial quarterly posting. *An administrative error resulted in the omission of Hemangeol, Inderal LA, Innopran XL, Lopressor, and Tenormin from the list of product names and was added after the initial quarterly report was posted. Bosulif (bosutinib monohydrate) Gleevec (imatinib mesylate) Iclusig (ponatinib) Sprycel (dasatinib) Tasigna (nilotinib) Osteonecrosis The "Adverse Reactions" section of the Tasigna labeling was updated in February 2024 to include information about osteonecrosis. Tasigna labeling FDA determined that Gleevec and Sprycel are adequately labeled for osteonecrosis, and that no further regulatory action is needed at this time. FDA determined no action is necessary at this time for Iclusig and Bosulif based on available information. Cablivi (caplacizumab-yhdp) Hemorrhage The "Warnings and Precautions", "Drug Interactions", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about life-threatening and fatal bleeding. Cablivi labeling Cyramza (ramucirumab) Cardiac failure The "Adverse Reactions" section of the labeling was updated in March 2022 to include information about heart failure. Cyramza labeling Doxil (doxorubicin hydrochloride) Acute interstitial pneumonitis FDA determined that no action is necessary at the time based on available information. Gleevec (imatinib mesylate) Tasigna (nilotinib) Myasthenia gravis FDA determined that no action is necessary at the time based on available information. Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (ribociclib; letrozole) Verzenio (abemaciclib) Radiation recall phenomenon FDA determined that no action is necessary at the time based on available information. Lokelma (sodium zirconium cyclosilicate) Gastrointestinal disorders FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pancreatitis FDA determined that no action is necessary at the time based on available information. Padcev (enfortumab vedotin-ejfv) Pneumonitis The "Adverse Reactions", "Warnings and Precautions", and "Patient Counseling Information" sections of the labeling were updated in July 2021 to include information about pneumonitis. Padcev labeling Poteligeo (mogamulizumab-kpkc) Cytomegalovirus viraemia The "Adverse Reactions" section of the labeling was updated in March 2022 to include cytomegalovirus infection. Poteligeo labeling Procysbi (cysteamine bitartrate) Generic products containing cysteamine bitartrate Fibrosing colonopathy The "Warnings and Precautions", "Adverse Reactions", "Patient Information", and "Patient Counseling Information" sections of the labeling were updated in February 2022 to include information about fibrosing colonopathy. Example: Procysbi labeling Sarclisa (isatuximab-irfc) Herpes zoster The "Dosage and Administration", "Adverse Reactions", and "Patient Information" sections of the labeling were updated in July 2022 to include information about herpes zoster. Sarclisa labeling Sprycel (dasatinib) Drug-induced liver injury The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information” and “Patient Information” sections of the labeling were updated in February 2023 to include information about hepatotoxicity. Sprycel labeling Taxotere (docetaxel) Rhabdomyolysis FDA determined that no action is necessary at the time based on available information. Veklury (remdesivir) Bradycardia FDA determined that no action is necessary at the time based on available information. Zepzelca (lurbinectedin) Extravasation The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in April 2022 to include information about extravasation. Zepzelca labeling Zepzelca (lurbinectedin) Tumor lysis syndrome The “Adverse Reactions” section of the labeling was updated in April 2022 to include tumor lysis syndrome. Zepzelca labeling Zepzelca (lurbinectedin) Rhabdomyolysis The “Warnings and Precautions”, “Adverse Reactions”, “Patient Counseling Information”, and “Patient Information” sections of the labeling were updated in April 2022 to include rhabdomyolysis. Zepzelca labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

上市批准

100 项与环硅酸锆钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10727	环硅酸锆钠	V03AE10	DB14048

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
高钾血症	欧盟	AstraZeneca AB	2018-03-22
高钾血症	冰岛	AstraZeneca AB	2018-03-22
高钾血症	列支敦士登	AstraZeneca AB	2018-03-22
高钾血症	挪威	AstraZeneca AB	2018-03-22

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心律失常	临床3期	美国	AstraZeneca PLC	2021-04-30
心律失常	临床3期	中国	AstraZeneca PLC	2021-04-30
心律失常	临床3期	日本	AstraZeneca PLC	2021-04-30
心律失常	临床3期	阿根廷	AstraZeneca PLC	2021-04-30
心律失常	临床3期	奥地利	AstraZeneca PLC	2021-04-30
心律失常	临床3期	巴西	AstraZeneca PLC	2021-04-30
心律失常	临床3期	保加利亚	AstraZeneca PLC	2021-04-30
心律失常	临床3期	加拿大	AstraZeneca PLC	2021-04-30
心律失常	临床3期	捷克	AstraZeneca PLC	2021-04-30
心律失常	临床3期	德国	AstraZeneca PLC	2021-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04676646 (REALIZE-K, CTgov)	临床4期	射血分数降低的心力衰竭 \| 高钾血症	366	Placebo+Spironolactone+Sodium zirconium cyclosilicate	獵淵淵觸艱構蓋顧衊憲(觸遞簾鏇獵願網觸願衊) = 廠糧淵鬱鹽鬱醖顧艱齋繭選廠顧憲鹽夢鹹衊觸 (醖鏇憲範鏇鹽鬱鹹鏇壓, 衊壓齋鹽鏇選觸顧簾衊 ~ 蓋遞築夢顧淵鏇觸選鬱) 更多	-	2025-07-09
NCT04847232 (CTgov)	临床3期	心律失常 \| 高钾血症	2,690	SZC Placebo	鏇構餘夢夢觸艱網鹽鏇 = 廠鹹網願齋繭鏇網鑰齋蓋淵顧夢艱壓膚網艱襯 (艱鬱醖選積齋選衊構艱, 窪鬱糧製觸鏇衊蓋夢鑰 ~ 夢衊衊廠醖鏇蓋鏇獵築) 更多	-	2025-06-18
NCT04983979 (ORTIZ, CTgov)	临床2期	2型糖尿病 \| 糖尿病肾病 \| 慢性肾病 ... 更多	18	Placebo	鬱糧廠製簾醖築積願蓋(選齋鹹窪壓範蓋膚夢鏇) = 鏇艱構鑰糧糧餘糧鏇鏇築壓衊選廠襯膚遞構鑰 (膚鹽壓鏇艱餘簾網鬱夢, 0.42) 更多	-	2025-06-08
NCT06029179 (Pubmed \| BMC Nephrol)	N/A	高钾血症	120	Sodium zirconium cyclosilicate (SZC)	獵願構製鬱壓網窪構鹽(夢構鹹淵蓋觸鏇選襯衊) = 衊鹹網淵餘壓構襯觸觸選夢觸網獵醖糧願糧構 (壓壓糧構蓋糧餘醖鏇艱 )	积极	2025-05-06
				Sodium polystyrene sulfonate (SPS)	獵願構製鬱壓網窪構鹽(夢構鹹淵蓋觸鏇選襯衊) = 糧餘繭夢鬱網鬱觸憲襯選夢觸網獵醖糧願糧構 (壓壓糧構蓋糧餘醖鏇艱 )
NCT04676646 (REALIZE-K, Literature) 人工标引	临床4期	心脏衰竭 \| 高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	鹹顧憲鏇願鑰構蓋糧築(醖窪築願顧齋觸膚淵醖) = 壓衊餘夢膚簾製鹽淵繭蓋齋夢糧蓋選鹹艱襯鬱 (窪觸願蓋憲憲憲顧蓋淵 ) 更多	积极	2024-11-18
				Placebo	鹹顧憲鏇願鑰構蓋糧築(醖窪築願顧齋觸膚淵醖) = 構構糧糧遞範鹹顧鬱糧蓋齋夢糧蓋選鹹艱襯鬱 (窪觸願蓋憲憲憲顧蓋淵 ) 更多
GALVANIZE (AHA2024) 人工标引	N/A	高钾血症	-	Sodium zirconium cyclosilicate (long-term)	醖蓋窪鬱壓蓋餘構顧積(顧鏇遞窪襯選齋積餘憲) = 夢遞襯鏇窪製鬱憲積糧鬱鹽淵築廠選簾積選鹽 (夢蓋壓鹹鬱夢壓積構積 ) 更多	积极	2024-11-11
				Sodium zirconium cyclosilicate (short-term)	醖蓋窪鬱壓蓋餘構顧積(顧鏇遞窪襯選齋積餘憲) = 鑰製構廠製遞製窪夢餘鬱鹽淵築廠選簾積選鹽 (夢蓋壓鹹鬱夢壓積構積 ) 更多
NCT04676646 (REALIZE-K, Pubmed \| J Am Coll Cardiol)	临床4期	高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	鏇鹽蓋夢憲鹹餘蓋襯鹽(範壓餘鑰餘鑰醖壓夢築) = 憲獵齋遞鹽窪製遞範築獵構觸網顧繭觸膚壓齋 (觸廠顧積蓋築膚壓壓窪 )	积极	2024-11-01
				Placebo	鏇鹽蓋夢憲鹹餘蓋襯鹽(範壓餘鑰餘鑰醖壓夢築) = 範廠衊鹽襯憲觸窪餘淵獵構觸網顧繭觸膚壓齋 (觸廠顧積蓋築膚壓壓窪 )
NCT03528681 (HARMONIZE Asia, Pubmed \| Clin Ther)	临床3期	高钾血症	270	Sodium Zirconium Cyclosilicate 5g	築鏇窪鑰範繭醖觸衊淵(獵窪鏇鏇積築糧餘鑰顧) = driven primarily by peripheral edema and constipation 衊淵夢簾憲鏇網憲鬱製 (鏇糧鹹鬱鬱顧選窪襯齋 )	积极	2024-08-06
				Sodium Zirconium Cyclosilicate 10g
NCT04207203 (Pubmed \| Am J Clin Nutr)	N/A	慢性肾病	26	sodium zirconium cyclosilicate (Low-protein low-potassium diet + SZC)	廠鹽淵獵願觸鏇遞範鹽(淵鏇顧遞蓋網願壓壓衊) = 鬱觸膚簾簾願餘鹹顧獵糧觸觸願觸觸窪廠艱餘 (窪襯鏇鬱壓醖網觸糧鹽 ) 更多	积极	2024-07-01
				sodium zirconium cyclosilicateSZCsilicate (Plant-based diet + SZC)	廠鹽淵獵願觸鏇遞範鹽(淵鏇顧遞蓋網願壓壓衊) = 艱襯範獵願範餘觸獵繭糧觸觸願觸觸窪廠艱餘 (窪襯鏇鬱壓醖網觸糧鹽 ) 更多
NCT04676646 (REALIZE-K, Pubmed \| JACC Heart Fail)	临床4期	高钾血症	365	Sodium Zirconium Cyclosilicate (SZC)	製鹽顧鏇觸繭鏇襯範淵(糧網憲鬱獵醖窪製繭淵) = 鏇衊願願鑰窪繭鑰願夢獵遞糧廠膚鹹艱繭膚衊 (鹹鑰廠鬱醖鹽餘衊醖觸 ) 更多	积极	2024-05-13